Proliferation News and Research

RSS

Inserm researchers successfully rejuvenate cells from elderly donors

Inserm's AVENIR "Genomic plasticity and aging" team, directed by Jean-Marc Lemaitre, Inserm researcher at the Functional Genomics Institute, has recently succeeded in rejuvenating cells from elderly donors.

4 Nov 2011

Scientists discover alternative mechanism for extension of telomeres

Scientists of the German Cancer Research Center have discovered an alternative mechanism for the extension of the telomere repeat sequence by DNA repair enzymes.

4 Nov 2011

Cancer cells maintain rapid proliferation due to PK-M2 enzyme

Cancer cells maintain their life-style of extremely rapid growth and proliferation thanks to an enzyme called PK-M2 (pyruvate kinase M2) that alters the cells' ability to metabolize glucose - a phenomenon known as the Warburg effect.

3 Nov 2011

Bacteria rapidly exchange genetic information related to human disease and antibiotic resistance

Much as people can exchange information instantaneously in the digital age, bacteria associated with humans and their livestock appear to freely and rapidly exchange genetic material related to human disease and antibiotic resistance through a mechanism called horizontal gene transfer (HGT).

2 Nov 2011

First study to show how H. pylori toxin can spur apoptosis

Researchers report they have figured out how the cancer-causing bacterium Helicobacter pylori attacks a cell's energy infrastructure, sparking a series of events in the cell that ultimately lead it to self-destruct.

2 Nov 2011

Researchers develop new 3D bone marrow culture systems

Stromal cells, as distinct from hematopoietic cells, are an essential component of the bone marrow microenvironment and are necessary for the long-term maintenance of hematopoietic stem cells (HSCs) in vitro.

2 Nov 2011

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced that it has initiated two Phase 1 clinical trials of IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. These two enzymes are implicated in hematologic cancers as well as a broad range of inflammatory conditions, which are the areas of focus within Infinity's PI3K clinical development program.

31 Oct 2011

Researchers shed light on inner workings of endocycle

An international team of researchers led by investigators in the U.S. and Germany has shed light on the inner workings of the endocycle, a common cell cycle that fuels growth in plants, animals and some human tissues and is responsible for generating up to half of the Earth's biomass.

31 Oct 2011

Scientists identify nicotinamidase enzyme as new drug target for Leishmaniasis

IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.

29 Oct 2011

Functional link between IKBKE and Akt activation in breast cancer

Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.

28 Oct 2011

RA drug reduces kidney cyst growth in ADPKD mouse model

Scientists at UC Santa Barbara have discovered that patients with an inherited kidney disease may be helped by a drug that is currently available for other uses.

28 Oct 2011

Spinal cord meninges is a potential source of self-renewing stem cells

Italian and Spanish scientists studying the use of stem cells for treating spinal cord injuries have provided the first evidence to show that meninges, the membrane which envelops the central nervous system, is a potential source of self-renewing stem cells.

28 Oct 2011

Inhibition of protein kinase B suppresses IKBKE's oncogenic transformation

28 Oct 2011

E. coli asparaginase linked to relapses in ALL patients with special form of ATF5 gene

One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia.

27 Oct 2011

Surgeons freeze organoid units and regenerate TESI for short bowel syndrome

Surgeons at Children's Hospital Los Angeles have conducted a study that could put regenerative tissue treatment for short bowel syndrome one step closer to the bedside. The researchers were able to successfully isolate and store organoid units and later generate tissue-engineered small intestine (TESI) in a mouse model. The groundbreaking results were presented at the 2011 Annual Clinical Congress of the American College of Surgeons.

27 Oct 2011

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular (“wet”) Age-related Macular Degeneration (AMD).

24 Oct 2011

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.

24 Oct 2011

Small molecule selectively blocks gene activity regulated by thyroid hormone

A small molecule developed at St. Jude Children's Research Hospital advances progress toward more tailored drugs in research that also offers insight into the biology of thyroid hormone.

22 Oct 2011

Critical migrating neurons in the human brain decline during infancy

José Manuel García Verdugo, full professor of Cell Biology at University of Valencia, together with a University of California research team, has participated in the discovery of new pathways of neurons migrating from lateral ventricles to the prefrontal cortex. The work done in chidren at early ages reveals a new cell pathway which may increase the amount of neurons in regions important for cognitive tasks, emotional processes and spatial perception.

22 Oct 2011